登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，4月8日，Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-04-09

  • Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus

    Deepak Jakhar & Ishmeet Kaur

    Nature Medicine (2020)

    To the Editor — In March 2020, in the midst of the COVID-19 pandemic1, reports that chloroquine (CQ) can inhibit the growth of severe acute respiratory syndrome coronavirus (SARS-CoV-2)2,3 have brought this molecule into the spotlight. Hydroxychloroquine (HCQS), which is typically used in dermatology clinics for the management of systemic lupus erythematosus (SLE) and has a better clinical safety profile and fewer drug–drug interactions than CQ, has also been demonstrated to have anti-SARS-CoV activity in vitro2,4. Now, amid the speculation regarding the beneficial roles of these molecules in COVID-19 treatment, shortages of CQ and HCQS are feared.

  • 原文来源：https://www.nature.com/articles/s41591-020-0853-0
107浏览量
原文链接
相关报告

  • 《LANCET，4月1日，Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-04-02
    • Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology Brian Owens Published:April 01, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30089-8 Excitement about a potential new treatment for the coronavirus disease 2019 (COVID-19) pandemic currently engulfing the world is causing problems for patients with arthritis and systemic lupus erythematosus (SLE), who routinely use the drug to control their symptoms. The antimalarial drug chloroquine and its safer derivative hydroxychloroquine have been used since the 1940s to treat autoimmune disorders, says Thomas Dörner, a rheumatologist at the Charité University Hospital in Berlin. Though the drug is rarely used for rheumatoid arthritis, around two-thirds of patients with SLE in Europe use hydroxychloroquine to manage their symptoms, and it is the only known therapy so far for primary Sjögren's syndrome, he says.
    98浏览量
    原文链接

  • 《Nature，4月23日，Obesity and impaired metabolic health in patients with COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-24
    • Obesity and impaired metabolic health in patients with COVID-19 Norbert Stefan, Andreas L. Birkenfeld, Matthias B. Schulze & David S. Ludwig Nature Reviews Endocrinology (2020) Preliminary data suggest that people with obesity are at increased risk of severe COVID-19. However, as data on metabolic parameters (such as BMI and levels of glucose and insulin) in patients with COVID-19 are scarce, increased reporting is needed to improve our understanding of COVID-19 and the care of affected patients. In China, older age (≥65 years) and the presence of comorbidities are associated with a more severe course of COVID-19 in patients infected with the novel coronavirus (SARS-CoV-2). Among the comorbid conditions, the highest fatality rate was found for cardiovascular disease (CVD) (10.5%) and diabetes mellitus (7.3%), followed by chronic respiratory diseases (6.3%), hypertension (6.0%) and cancer (5.6%)1. A direct endocrine and metabolic link between hypertension and diabetes mellitus and coronavirus infection, which might involve angiotensin-converting enzyme 2, is being discussed2.
    96浏览量
    原文链接